Q&A with Zoltan Fehervari

We meet Zoltan, Senior Editor at Nature Immunology, to find out about his career so far and his interest in the cancer-immune setpoint.

Go to the profile of Dr Alison Halliday
May 30, 2018
0

1. What is your full name, job title and where do you work?

My name is Zoltan Fehervari, Senior Editor at Nature Immunology. I’m based primarily in London but get around quite a bit to other offices around the world.

2. Describe your job in a tweet

Reading about and publishing fascinating science (rejecting is also a big component…)

3. What does it involve?

I tend to cover much of the cancer immunology output at the journal but we’re pretty much expected to handle all aspects of immunology from apoptosis to zoonosis.

4. Describe a typical day at work

Can be very varied… Reading, writing, travelling, speaking, teaching, interacting with scientists, conferences, special projects (like the cancer-immune setpoint)… But mainly reading papers and making decisions about whether to accept or reject.

5. Tell us a bit about your career so far

A somewhat meandering story arc - I started out as a marine zoologist before jumping ship (no pun intended) to immunology, a stint in pharma and two postdocs studying immunoregulation at the Universities of Cambridge and Kyoto. I’ve been in science publishing for >10 years and haven’t looked back since.

6. What are you most proud of?

Professionally, I do get a kick out of publishing a standout paper. While I’m only the tiniest cog in the paper – and right at the end of the process – I still get a sense of ownership especially when I’ve helped shepherd a great paper through to publication.

7. What’s your interest in the cancer-immune setpoint? 

I was involved in some of the original design of the project, as well as contributing material. I'm now prepping an upcoming webcast and video.

8. What do you hope it will achieve?

I hope it helps to engage the community, harvest collective wisdom and accelerate/facilitate dissemination of cancer-immune related data. Hopefully this model will inspire similar future projects to synthesize complex fields and diseases.

9. What are your hopes for the future of cancer immunotherapy?

Guardedly positive. There’s been some amazing progress but like Frodo setting out from the Shire - we still have a long way to go.

10. What advice do you have for those working in this field?

Stay focused and don’t be disheartened by set-backs.

11. What do you do to wind down?

Winding up my kids!

12. Tell us something unusual about yourself

I’m pretty handy with a pair of nunchaku. 

Go to the profile of Dr Alison Halliday

Dr Alison Halliday

Community Manager, Nature Research

Molecular Biologist turned freelance science communicator, with 10 year's experience at Cancer Research UK.

No comments yet.